As the COVID-19 epidemic continues, the whole society is reconsidering how humans live in harmony with wildlife.

Recently, YaoPharma joined the public welfare project of "Protect endangered animals with benevolence of pharmaceutical practitioner "initiated by the World Animal Protection, and signed the commitment letter of "wildlife-friendly” pharmaceutical enterprises.

At the signing ceremony, YaoPharma made the commitment to reject endangered wildlife ingredients in the production, development and sales of APIs and finished products, and to encourage consumers not to buy or use medicines and healthcare products containing endangered wildlife ingredients.

Scientist Dr. Sun Quanhui of the World Animal Protection said that driven by interests, a large number of wild animals are killed or bred in captivity for medicinal purposes every year, causing great suffering to animals and seriously threatening the survival of species in the wild. The outbreak of COVID-19 is a reminder of the huge risks to public health posed by the hunting, breeding, transportation and use of wild animals, as well as the dangers of using wild animals in medicine. As a leading pharmaceutical enterprise in APIs and finished products, the signing of the "wildlife-friendly” pharmaceutical enterprises commitment by YaoPharma not only demonstrates the corporate social responsibility to protect wildlife, but also has a leading and exemplary effect in promoting more enterprises to support animal protection.

The vice-president of YaoPharma Li Hongyi said, as a key national high-tech enterprise in the pharmaceutical industry, YaoPharma not only focus on the health and well-being of human beings, but also undertakes social and environmental responsibilities. The signing of the "wildlife-friendly” pharmaceutical enterprises commitment is an important contribution to the protection of wildlife.

The two sides held an online signing ceremony

During 2018 to 2019, with the support of the World Animal Protection, Deloitte and PricewaterhouseCoopers conducted independent studies on the risks related to the use of endangered wild animals to produce medicine and the impact of abandoning the business of endangered wild animal products on enterprises. The results showed that the enterprises that produce, sell and invest in endangered wildlife drugs faced multiple risks such as policy, market, public opinion, industrial environment and finance. Based on this, the World Animal Protection and PricewaterhouseCoopers jointly launched the "Protect endangered animals with benevolence of pharmaceutical practitioner" public welfare project, which calls on relevant enterprises to stop the production and sale of medicines and healthcare products containing endangered wildlife ingredients, and support humane substitutes such as herbs and biological drugs to jointly protect wildlife.

So far, three Chinese pharmaceutical enterprises, including YaoPharma, have signed the commitment to join the ranks of "wildlife-friendly" pharmaceutical enterprises.

World Animal Protection is an international non-profit organization headquartered in London that carry out animal protection work in more than 50 countries and regions. World Animal Protection has full consultative status at the United Nations and has permanent representatives at the United Nations, the European parliament and the African union. World Animal Protection promote the joint protection of animals with scientific, rational and cooperative attitude.

YaoPharma, with its headquarter located in Chongqing Liangjiang New Area- a national level new area, is a full-chain pharmaceutical manufacturer integrated with R&D, manufacturing and marketing & sales. Its finished dosage forms are successfully launched to US and Canadian markets, completed the industrial upgrade from API export to API & finished products export. It has formed the brand effect of YaoPharma products and the company, as well as the core competitiveness of high-tech, high-standard, professional and international.